How Clinical Data Can Predict a COVID-19 Vaccine Launch

Recap of WatersTechnology Article, [Vaccine Tracking Data—The Next Big Alt Dataset](#). Published July 31, 2020.

Each day, we are getting closer to discovering a vaccine for COVID-19, and everyone wants to know who will be first to market. Companies are leveraging data analytics to predict the answer.

> The US government is taking big bets by supporting pharmaceutical companies with billions of dollars in funding.
>
> Financial companies want to know where to invest.
>
> Pharma and biotech companies need to formulate their competitive advantage.

[WatersTechnology](#), a leader in global financial news and analysis, recently published an article about how alternative data sources could provide investors with signals for a COVID-19 vaccine launch. In their interview with Beau Bush, founder of Ozmosi, they learned about BEAM, a data analytics platform that can predict market activity.

The BEAM tool uses natural language processing (NLP) to track drugs and vaccines from the pre-clinical stage through commercialization. By "cleaning" data from millions of clinical trials across the globe on a daily basis, Ozmosi has the ability to offer clients the most relevant, point-in-time data that is critical to predicting the next big breakthrough.

"It is really hard to tell if a company has what looks like 20 different drugs, or if it's really just three. Once you clean up the data, that opens up the opportunity to assess the marketplace."

– Beau Bush, Founder, Ozmosi

The data output from BEAM allows analysts to drill into market predictors needed for critical decision-making, such as innovation risk, launch timing vs competition, and likelihood of success.

[BEAM by Ozmosi](#) is one of many data analytics tools available on the market today. With global clinical data at its core, investors, pharmaceutical companies, and biotechs benefit from a level of insight that is unmatched for predicting success in the healthcare space.

With thousands of clinical trials in play for COVID-19, time – and data – are of the essence.